Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-5576
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.36 million
Profitability
Miscellaneous
Employees53
OptionableNot Optionable
Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions
What is Unum Therapeutics' stock symbol?
Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."
How were Unum Therapeutics' earnings last quarter?
Unum Therapeutics Inc (NASDAQ:UMRX) posted its quarterly earnings data on Monday, November, 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.01. The business had revenue of $2.04 million for the quarter, compared to analysts' expectations of $2.29 million. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. View Unum Therapeutics' Earnings History.
When is Unum Therapeutics' next earnings date?
What price target have analysts set for UMRX?
5 Wall Street analysts have issued 1 year target prices for Unum Therapeutics' stock. Their predictions range from $18.00 to $21.00. On average, they anticipate Unum Therapeutics' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 384.3% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.
What is the consensus analysts' recommendation for Unum Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.
Has Unum Therapeutics been receiving favorable news coverage?
Media headlines about UMRX stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Unum Therapeutics earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Unum Therapeutics' key competitors?
Some companies that are related to Unum Therapeutics include Obseva (OBSV), Theratechnologies (THERF), BioSpecifics Technologies (BSTC), Prothena (PRTA), Forty Seven (FTSV), Innate Pharma (IPHYF), Odonate Therapeutics (ODT), Corium International (CORI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Eidos Therapeutics (EIDX), Akorn (AKRX), Clementia Pharmaceuticals (CMTA), Evolus (EOLS) and Corbus Pharmaceuticals (CRBP).
Who are Unum Therapeutics' key executives?
Unum Therapeutics' management team includes the folowing people:
- Dr. Charles Wilson, CEO & Director (Age 53)
- Ms. Christiana Stamoulis, Pres & CFO (Age 47)
- Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 54)
- Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
- Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 53)
When did Unum Therapeutics IPO?
(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.
How do I buy shares of Unum Therapeutics?
Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unum Therapeutics' stock price today?
One share of UMRX stock can currently be purchased for approximately $4.13.
How big of a company is Unum Therapeutics?
Unum Therapeutics has a market capitalization of $127.46 million and generates $8.36 million in revenue each year. Unum Therapeutics employs 53 workers across the globe.
What is Unum Therapeutics' official website?
How can I contact Unum Therapeutics?
Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]
MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)
MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote "Outperform" if you believe UMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
